The application of CAR-T cell therapy in hematological malignancies: advantages and challenges

作     者：Zijun Zhao Yu Chen Ngiambudulu M.Francisco Yuanqing Zhang Minhao Wu 

作者机构：Zhongshan School of MedicineSun Yat-sen University School of Pharmaceutical SciencesSun Yat-sen University 

出 版 物：《Acta Pharmaceutica Sinica B》 (药学学报（英文版）)

年 卷 期：2018年第8卷第4期

页      面：539-551,704页

核心收录：

学科分类：1007[医学-药学(可授医学、理学学位)] 1004[医学-公共卫生与预防医学(可授医学、理学学位)] 1002[医学-临床医学] 1001[医学-基础医学(可授医学、理学学位)] 100214[医学-肿瘤学] 10[医学] 

基　　金：supported by grants from the National Natural Science Foundation of China (Nos. 31670880 and 31370868) the Guangdong Natural Science Fund for Distinguished Young Scholars (No. 2016A030306004) Guangdong Special Support Program for Youth Science and Technology Innovation Talents (No. 2015TQ01R473) Guangzhou Pearl River New Star Program (No. 201610010064) Guangdong Innovative Research Team Program (No. 2011Y035) 

主　　题：Chimeric antigen receptor T cell Clinical applications Immunotherapy Malignancies 

摘      要：Chimeric antigen receptor T cell(CAR-T cell) therapy is a novel adoptive immunotherapy where T lymphocytes are engineered with synthetic receptors known as chimeric antigen receptors(CAR).The CAR-T cell is an effector T cell that recognizes and eliminates specific cancer cells, independent of major histocompatibility complex molecules. The whole procedure of CAR-T cell production is not well understood. The CAR-T cell has been used predominantly in the treatment of hematological malignancies,including acute lymphoblastic leukemia, chronic lymphocytic leukemia, lymphoma, and multiple myeloma. Solid tumors including melanoma, breast cancer and sarcoma offer great promise in CAR-T cell research and development. CD19 CAR-T cell is most commonly used, and other targets, including CD20, CD30, CD38 and CD138 are being studied. Although this novel therapy is promising, there are several disadvantages. In this review we discuss the applications of CAR-T cells in different hematological malignancies, and pave a way for future improvement on the effectiveness and persistence of these adoptive cell therapies.